After ibrutinib treatment, T cells show decreased expression of the inhibitory receptors PD-1 and CTLA-4, Treg numbers are decreased, and anti-tumor TH1 responses are increased [104,116]. This evidence concerns the gene CTLA4 and neoplasm.